Table of Contents
Table of Contents
Preface
List of Contributors
PART I
Chapter 1 – Voriconazole: Synthesis and Mechanism of Action (pp. 3-8)
Antonios Papadopoulos and Efthymia Giannitsioti (Fourth Department of Internal Medicine and Infectious Diseases, Athens University Medical School, ATTIKON University General Hospital, Athens, Greece)
Chapter 2 – Action of Voriconazole In Vitro and In Vivo (pp. 9-12)
Efthymia Giannitsioti, MD, PhD and Antonios Papadopoulos, MD, PhD (Fourth Department of Internal Medicine and Infectious Diseases, Athens University Medical School, ATTIKON University General Hospital, Athens, Greece)
Chapter 3 – Voriconazole: Pharmacokinetics, Dosage and Administration (pp. 13-28)
Rod Everett Quilitz (Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA)
PART II
Chapter 4 – Antifungal Therapy with Voriconazole for Aspergillosis (pp. 29-40)
Malgorzata Mikulska, Paola Tatarelli and Claudio Viscoli (Division of Infectious Diseases, University of Genoa, IRCCS San Martino-IST, Genoa, Italy)
Chapter 5 – Voriconazole Treatment in Invasive Candidiasis (pp. 41-52)
Pierluigi Viale, MD, PhD, and Russell E. Lewis, MD, PhD (Department of Medical Sciences and Surgery, Infectious Diseases Unit- S. Orsola Malpighi Hospital, University of Bologna, Italy)
Chapter 6 – Antifungal Therapy with Voriconazole for Esophageal Candidiasis (pp. 53-58)
Jack D. Sobel, MD (Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA)
Chapter 7 – Voriconazole in Orthopaedics: Osteomyelitis and Antifungal-Loaded Bone Cement (pp. 59-82)
Andrea Angelini, MD, Todd Bertrand, MD, Alessandra Maso and Pietro Ruggieri, MD PhD (University of Bologna, Rizzoli Orthopedic Institute, Department of Orthopedics, Bologna, Italy, and others)
Chapter 8 – Voriconazole for Endemic Fungal Infection (Disseminated Histoplasmosis, Blastomycosis, Coccidioidomycosis and Paracoccidioidomycosis) (pp. 83-94)
Antonios Papadopoulos, MD, PhD and Efthymia Giannitsioti, MD (Fourth Department of Internal Medicine and Infectious Diseases, Athens University Medical School, ATTIKON University General Hospital, Athens, Greece)
Chapter 9 – Use of Voriconazole As Antifungal Prophylaxis and Empirical Therapy During Chemotherapy in Immunodepressed Patients and in Solid Organ Transplantation (pp. 95-102)
Efthymia Giannitsioti, MD, PhD and Antonios Papadopoulos, MD, PhD (Fourth Department of Internal Medicine and Infectious Diseases, Athens University Medical School, ATTIKON University General Hospital, Athens, Greece)
Chapter 10 – Use of Voriconazole in Pediatric Patients with Cancer (pp. 103-110)
Pierluigi Brazzola, MD, and Mario Renato Rossi, MD (Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland)
PART III
Chapter 11 – Voriconazole: Contraindications, Warnings and Precautions, Adverse Reactions (pp. 113-128)
Antonios Papadopoulos, MD, PhD,, Andreas F. Mavrogenis, MD, PhD and Efthymia Giannitsioti, MD (Fourth Department of Internal Medicine and Infectious Diseases, Athens University Medical School, ATTIKON University General Hospital, Athens, Greece)
Chapter 12 – Drug Interactions with Voriconazole (pp. 129-140)
Russell E. Lewis, and Pierluigi Viale, MD, PhD (Department of Medical Sciences and Surgery, Infectious Diseases Unit- S. Orsola Malpighi Hospital, University of Bologna, Italy)
Chapter 13 – Drug Resistance Against Voriconazole (pp. 141-144)
Efthymia Giannitsioti, MD, PhD and Antonios Papadopoulos, MD, PhD (Fourth Department of Internal Medicine and Infectious Diseases, Athens University Medical School, ATTIKON University General Hospital, Athens, Greece)
Chapter 14 – Voriconazole Toxicology (pp. 145-154)
Russell E. Lewis, and Pierluigi Viale, MD, PhD (Department of Medical Sciences and Surgery, Infectious Diseases Unit- S. Orsola Malpighi Hospital, University of Bologna, Italy)
Chapter 15 – Therapeutic Drug Monitoring of Voriconazole (pp. 155-166)
Russell E. Lewis, and Pierluigi Viale, MD, PhD (Department of Medical Sciences and Surgery, Infectious Diseases Unit- S. Orsola Malpighi Hospital, University of Bologna, Italy)
Chapter 16 – Pharmacoeconomics of Voriconazole (pp. 167-184)
Daoud Al-Badriyeh (College of Pharmacy, Qatar University, Doha, Qatar)
Index
Audience: Infectious diseases physicians; Community ophthalmologists; Family physicians; General internists and other primary care professionals; Pneumologists; Pediatricians, Orthopaedic and General Surgeons, Dermatologists Physicians training or in practice in Occupational and Environmental Medicine (OEM); also useful to other professionals in occupational health including nurses, industrial hygienists, toxicologists, and safety professionals; Health Educators; Infection Control Professionals; HIV/ID.